New population-based case-control data published in Plos One suggests cannabis consumers are less likely to suffer from non-alcoholic fatty liver disease (NAFLD), which is the most prevalent form of liver disease in humans. Researchers from the University of Massachusetts Medical School and John Hopkins University in Baltimore analyzed the relationship between cannabis use and NAFLD in a group of 5.9 million hospitalized patients over 18 across the nation. NAFLD was 15% lower in occasional marijuana users that non-users, and 52% lower in habitual users. Researchers wrote, “We observed a strong dose-dependent reduction in the prevalence of NAFLD with cannabis use suggesting that cannabis use might suppress or reverse NAFLD development.”
This information has been provided by the Daily Chronic and approved by our Chief Medical Officer.